891 Results
Sort By:
Published on March 20, 2024
Researchers at the University of California, Irvine (UCI), have uncovered the significant roles of two enzymes, APOBEC3A and APOBEC3B, in creating mutations within cancer genomes, opening up new avenues for developing targeted intervention strategies in cancer treatment. Reporting in Nature Communications, the study highlights how these enzymes modify the DNA…
Published on March 13, 2024
Researchers at the Massachusetts Institute of Technology (MIT) report that their new approach of using CRISPR-based prime editing provides a faster and more efficient way to screen for cancer mutations in individual genes in their natural setting. This will allow researchers to better understand the role those mutations play in…
Published on March 24, 2023
A multicenter research and development effort led by a team of neurosurgeons and engineers at Michigan Medicine at the University of Michigan (U-M) have developed a screening system call DeepGlioma that employs rapid imaging plus artificial intelligence (AI) to detect brain cancer mutations in under 90 seconds. “This AI-based tool…
Published on September 19, 2018
Artificial intelligence has a way of inspiring wonder and uneasiness at the same time, particularly when it shows that it can outperform humans while hiding exactly how it goes about its business. The latest group of humans to be mysteriously surpassed by artificial intelligence, or AI, consists of pathologists—specifically, pathologists…
Published on September 5, 2017
A study published today by researchers at Memorial Sloan Kettering Cancer Center (MSK) has concluded that simultaneous sequencing of tumor DNA and normal tissue for a broad panel of cancer-related genes may detect more potentially clinically significant heritable mutations than a targeted approach based on current clinical guidelines. The study…
Published on January 3, 2017
A new study led by scientists from the Icahn School of Medicine at Mount Sinai have just published data that shows mutations linked to endometrial cancer can be found in the uterine lavage fluid of pre- and post-menopausal women both with and without detectable cancer. The findings from the new…
Published on January 17, 2024
Research led by the Wellcome Sanger Institute and the University of Cambridge suggests that more than one kind of genetic mutation is needed to develop a rare blood cancer known as a myeloproliferative neoplasm (MPN). MPNs are a group of rare blood cancers that involve over production of mature blood…
Published on September 27, 2023
One of the largest research efforts studying genes associated with prostate cancer reveals that mutations in 11 genes are associated with aggressive disease. The study, which analyzed samples from 17,500 cancer patients and published in JAMA Oncology, found mutations in several genes not already included in common prostate cancer genetic…
Published on April 5, 2023
New evidence finds nine germline pathogenic variants, combined with H. pylori infection, raise gastric cancer risk considerably. Several of these variants are involved in homologous-recombination. It has been estimated that germline mutations cause only one to three percent of gastric cancers. These new findings suggest hereditary risk is more important…
Published on February 16, 2023
New evidence shows that germline-somatic associations can affect cancer development. In a large-scale analysis of data from the Dana-Farber Cancer Institute across 11 cancer types, researchers found that certain variants were associated with a decreased risk of somatic mutations, while others were linked to a higher risk. This study appeared…
Published on January 30, 2023
Stemline Therapeutics, a subsidiary of pharma and diagnostics company Menarini Group, has received approval from the FDA for elacestrant (trade name Orserdu) for the treatment of postmenopausal women or adult men with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine…
Published on January 20, 2023
A massive, multinational genomic study has uncovered several genetic mutations that operate through specific biological pathways to increase susceptibility to sarcoma cancers. The genetic variants increased the risk of inherited sarcomas by altering telomere biology and mitotic function, both of which are fundamental to chromosome integrity. The findings, outlined in…
Published on November 16, 2022
Breast and ovarian cancers with a BRCA mutation are known to recur at a high rate after initial treatment. Now, a team of researchers at the University of Pennsylvania have discovered factors that may predispose breast and ovarian cancers associated with BRCA1/2 gene mutations that make them more likely to…
Published on July 8, 2022
Two of the most common genetic changes that cause cells to become cancerous, which were previously thought to act separately, are working in concert. A team led by University of Wisconsin–Madison cancer researchers, Richard A. Anderson and Vincent Cryns, has described a direct link between the p53 and PI3K/Akt pathways…
Published on June 29, 2022
The LUNGevity Foundation announced this week it has launched the Rare Mutations and Fusions Lung Cancer Patient Gateway that will provide patients with non-small cell lung cancer (NSCLC)—and their caregivers—with information on best treatment options, as well as access to educational webinars and support from the community of gateway users.…